Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome
Corresponding Author
Etsuro Matsubara MD, PhD
Department of Neurology, Gunma University School of Medicine, Gunma, Japan
Department of Neurology, Gunma University School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, JapanSearch for more papers by this authorJorge Ghiso PhD
Department of Pathology, New York University Medical Center, New York, NY
Search for more papers by this authorBlas Frangione MD, PhD
Department of Pathology, New York University Medical Center, New York, NY
Search for more papers by this authorMasakuni Amari MD, PhD
Department of Neurology, Gunma University School of Medicine, Gunma, Japan
Search for more papers by this authorYasushi Tomidokoro MD
Department of Neurology, Gunma University School of Medicine, Gunma, Japan
Search for more papers by this authorYoshio Ikeda MD
Department of Neurology, Gunma University School of Medicine, Gunma, Japan
Search for more papers by this authorYasuo Harigaya MD, PhD
Department of Neurology, Gunma University School of Medicine, Gunma, Japan
Search for more papers by this authorKoichi Okamoto MD, PhD
Department of Neurology, Gunma University School of Medicine, Gunma, Japan
Search for more papers by this authorMikio Shoji MD, PhD
Department of Neurology, Gunma University School of Medicine, Gunma, Japan
Search for more papers by this authorCorresponding Author
Etsuro Matsubara MD, PhD
Department of Neurology, Gunma University School of Medicine, Gunma, Japan
Department of Neurology, Gunma University School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, JapanSearch for more papers by this authorJorge Ghiso PhD
Department of Pathology, New York University Medical Center, New York, NY
Search for more papers by this authorBlas Frangione MD, PhD
Department of Pathology, New York University Medical Center, New York, NY
Search for more papers by this authorMasakuni Amari MD, PhD
Department of Neurology, Gunma University School of Medicine, Gunma, Japan
Search for more papers by this authorYasushi Tomidokoro MD
Department of Neurology, Gunma University School of Medicine, Gunma, Japan
Search for more papers by this authorYoshio Ikeda MD
Department of Neurology, Gunma University School of Medicine, Gunma, Japan
Search for more papers by this authorYasuo Harigaya MD, PhD
Department of Neurology, Gunma University School of Medicine, Gunma, Japan
Search for more papers by this authorKoichi Okamoto MD, PhD
Department of Neurology, Gunma University School of Medicine, Gunma, Japan
Search for more papers by this authorMikio Shoji MD, PhD
Department of Neurology, Gunma University School of Medicine, Gunma, Japan
Search for more papers by this authorAbstract
About 90% of the soluble amyloid β (sAβ) that circulates in normal human plasma is associated with lipoprotein particles. In sporadic Alzheimer's disease patients, free sAβ42 but not sAβ40 is increased approximately 2.3-fold compared with age-matched controls, although a more marked elevation (approximately 8-fold for free sAβ40 and about 20-fold for sAβ42) is found in Down's syndrome patients. The data suggest that lipoprotein-sAβ dissociation may contribute to the influx of sAβ into the brain as a result of decreased plasma clearance. Ann Neurol 1999;45:537–541
References
- 1 Shoji M, Golde TE, Ghiso J, et al. Production of the Alzheimer amyloid β protein by normal proteolytic processing. Science 1992; 258: 126–129
- 2 Seubert P, Vigo-Pelfrey C, Esch F, et al. Isolation and quantification of soluble Alzheimer's β peptide from biological fluids. Nature 1992; 359: 325–327
- 3 Vigo-Pelfrey C, Lee D, Keim P, et al. Characterization of β-amyloid peptide from human cerebrospinal fluid. J Neurochem 1993; 61: 1965–1968
- 4 Ghiso J, Calero M, Matsubara E, et al. Alzheimer's soluble amyloid β is a normal component of human urine. FEBS Lett 1997; 408: 105–108
- 5 Tabaton M, Nunzi MG, Xue R, et al. Soluble amyloid β-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem Biophys Res Commun 1994; 200: 1598–1603
- 6 Näslund J, Schierhorn A, Hellman U, et al. Relative abundance of Alzheimer Aβ amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci USA 1994; 91: 8378–8382
- 7 Teller JK, Russo C, DeBusk L, et al. Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med 1996; 2: 93–95
- 8 Koudinov A, Matsubara E, Frangione B, Ghiso J. The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma. Biochem Biophys Res Commun 1994; 205: 1164–1171
- 9 Matsubara E, Frangione B, Ghiso J. Characterization of apolipoprotein J–Alzheimer's Aβ interaction. J Biol Chem 1995; 270: 7563–7567
- 10 Matsubara E, Soto C, Governale S, et al. Apolipoprotein J and Alzheimer's amyloid β solubility. Biochem J 1996; 316: 671–679
- 11 Biere AL, Ostaszewski B, Stimson ER, et al. Amyloid β peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem 1996; 271: 32916–32922
- 12 McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939–944
- 13 Suzuki N, Cheung TT, Cai XD, et al. An increased percentage of long amyloid β protein secreted by familial amyloid β protein precursor (βAPP717) mutants. Science 1994; 264: 1336–1340
- 14 Asami-Odaka A, Ishibashi Y, Kikuchi T, et al. Long amyloid β-protein secreted from wild-type human neuroblastoma IMR-32 cells. Biochemistry 1995; 34: 10272–10278
- 15 Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid β-protein similar to that in senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996; 2: 864–870
- 16 Busciglio J, Gabuzda DH, Matsudaira P, Yankner BA. Generation of β-amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc Natl Acad Sci USA 1993; 90: 2092–2096
- 17 Tamaoka A, Sawamura N, Fukushima T, et al. Amyloid β protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Sci 1997; 148: 41–45
- 18 Tokuda T, Fukushima T, Ikeda S, et al. Plasma levels of amyloid β proteins Aβ1–40 and Aβ1–42(43) are elevated in Down's syndrome. Ann Neurol 1997; 41: 271–273
- 19 Zlokovic BV, Ghiso J, Mackic JB, et al. Blood-brain barrier transport of circulating Alzheimer's amyloid β. Biochem Biophys Res Commun 1993; 197: 1034–1040
- 20 Maness LM, Banks WA, Podlisny MB, et al. Passage of human amyloid β protein 1-40 across the murine blood-brain barrier. Life Sci 1994; 55: 1643–1650
- 21 Ghilardi JR, Catton M, Stimson ER, et al. Intra-arterial infusion of [125I] Aβ1–40 labels amyloid deposits in the aged primate brain in vivo. Neuroreport 1996; 7: 2607–2611
- 22 Kosaka T, Imagawa M, Seki K, et al. The βAPP717 Alzheimer mutation increases the percentage of plasma amyloid-β protein ending at Aβ42(43). Neurology 1997; 48: 741–745
Citing Literature
